{
    "clinical_study": {
        "@rank": "124398", 
        "arm_group": {
            "arm_group_label": "Dovitinib plus docetaxel", 
            "arm_group_type": "Experimental", 
            "description": "In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off\nIn phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
        }, 
        "brief_summary": {
            "textblock": "Docetaxel is currently one of standard second-line therapy in patients with gastric cancer.\n      As angiogenesis and FGFR pathway has been suggested to be associated with gastric cancer,\n      dovitinib, dual VEGFR and FGFR inhibitor, may have the potential to improve the outcomes of\n      patients with gastric cancer. Therefore, we investigated the combination regimen of\n      docetaxel and dovitinib."
        }, 
        "brief_title": "Dovitinib Plus Docetaxel in Gastric Cancer", 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Pathologically proven metastatic or unresectable adenocarcinoma of stomach or\n             gastroesophageal junction\n\n          2. Patients with progressive disease (radiological confirmation required) after one line\n             of chemotherapy except taxane for advanced gastric cancer in palliative setting\n\n          3. Presence of at least one evaluable disease by Response Evaluation Criteria in Solid\n             Tumors (RECIST) version 1.1\n\n          4. Age of 18 to 74 years\n\n          5. Estimated life expectancy of more than 3 months\n\n          6. Eastern Cooperative Oncology Group (ECOG) performance status 0~2\n\n          7. Adequate bone marrow function (Absolute neutrophil counts \u2265 1,500/uL, hemoglobin \u2265\n             8.0g/dL, and platelet \u2265 100,000/uL)\n\n          8. Adequate renal function (creatinine < 1.5mg/dL)\n\n          9. Adequate hepatic function (total bilirubin < 1.5 mg/dL, transaminase < 3 times the\n             upper normal limit [5 times for patients with liver metastasis])\n\n         10. No prior anti-angiogenic therapy (anti-VEGF or VEGFR tyrosine kinase inhibitor etc)\n             or FGF/FGFR inhibitor\n\n         11. No prior radiation therapy within 4 weeks of the study (Irradiated lesions should not\n             be included in the evaluable lesions.)\n\n         12. Written informed consent\n\n        Exclusion Criteria:\n\n          1. Past or concurrent history of neoplasm other than gastric adenocarcinoma, except for\n             curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri\n\n          2. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             prior to study treatment start\n\n          3. Bowel obstruction\n\n          4. Evidence of serious gastrointestinal bleeding\n\n          5. Presence of central nervous system (CNS) metastasis\n\n          6. History of significant neurologic or psychiatric disorders\n\n          7. Significant cardiac disease within 6 months of the study (congestive heart failure\n             uncontrollable by medication, symptomatic coronary heart disease, or arrhythmia,\n             myocardial infarction)\n\n          8. Left ventricular ejection fraction (LVEF) assessed by 2-D echocardiogram (ECHO) or\n             multiple gated acquisition scan (MUGA), < 45%\n\n          9. Uncontrolled hypertension defined by a SBP \u2265 160 mm Hg and/or DBP \u2265 100 mm Hg, with\n             or without anti-hypertensive medication. Initiation or adjustment of antihypertensive\n             medication (s) is allowed prior to study entry.\n\n         10. QTc > 480 msec on screening ECG\n\n         11. Proteinuria defined by NCI CTCAE grade > 1 at baseline as measured by a urine\n             dipstick (2+ or greater) and confirmed by a 24 hour urine collection ( > 1g/24hrs).\n             Subjects may be re-screened if blood pressure is shown to be controlled with or\n             without intervention\n\n         12. History of thrombotic or bleeding diathesis or coagulopathy\n\n         13. Serious non-healing wound, peptic ulcer, or bone fracture\n\n         14. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6\n             months\n\n         15. Pregnant or lactating women, women of childbearing potential not employing adequate\n             contraception\n\n         16. Other serious illness or medical conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921673", 
            "org_study_id": "AMC1302"
        }, 
        "intervention": {
            "arm_group_label": "Dovitinib plus docetaxel", 
            "description": "In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off\nIn phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used.", 
            "intervention_name": "Dovitinib and docetaxel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastric cancer", 
            "Phase I/II", 
            "Second-line chemotherapy", 
            "Dovitinib", 
            "Docetaxel", 
            "Refractory to first-line chemotherapy"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "email": "ykkang@amc.seoul.kr", 
                "last_name": "Yoon-Koo Kang, M.D., Ph.D.", 
                "phone": "+82-2-3010-3230"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Yoon-Koo Kang, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Min-Hee Ryu, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ryoo Back-Yeol, MD,PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Park Sook-Ryun, MD,PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I-II Trial of Dovitinib Plus Docetaxel as Second-line Chemotherapy in Patients With Metastatic or Unresectable Gastric Cancer After Failure of First-line Chemotherapy", 
        "overall_contact": {
            "email": "ykkang@amc.seoul.kr", 
            "last_name": "Yoon-Koo Kang, M.D., Ph.D.", 
            "phone": "+82-2-3010-3230"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Yoon-Koo Kang, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "If dose limiting toxicities are experienced in two or more out of six patients in the cohort (more than 33% of patient cohort), that dose will be defined as the maximum tolerated dose.", 
                "measure": "Maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Progression-free survival is defined as the time from the first treatment to the onset of progressive disease or to the date of death whichever comes first.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 year"
            }
        ], 
        "reference": [
            {
                "PMID": "17520252", 
                "citation": "Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, Kim BS, Kim M, Chun YJ, Lee JS, Kang YK. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol. 2008 Apr;61(4):631-7. Epub 2007 May 23."
            }, 
            {
                "PMID": "9701011", 
                "citation": "Yamamoto S, Yasui W, Kitadai Y, Yokozaki H, Haruma K, Kajiyama G, Tahara E. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int. 1998 Jul;48(7):499-506."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921673"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Yoon-Koo Kang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of patients with complete and partial response according to the Response Evaluation Criteria in Solid Tumors version 1.1", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "2 year"
            }, 
            {
                "description": "Adverse events caused by study drugs according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Time from start of study treatment to any cause of death", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "FGFR2 copy number will be evaluated in blood and tumor tissue. Treatment efficacy including overall response rate, progression-free survival, and overall survival will be compared according to FGFR2 copy number determined by both FISH and real time PCR using TaqMan probe.", 
                "measure": "Biomarker", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 2 weeks after study treatment"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}